The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Diabetes-related foot ulcers (DFUs) and their sequelae result in large patient and societal burdens. Long-term data determining the efficacy of individual glucose-lowering agents on DFUs are lacking. Using existing data from the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, we conducted post hoc analyses assessing the impact of liraglutide versus placebo in people with type 2 diabetes and at high risk of cardiovascular (CV) events on the incidence of DFUs and their sequelae. RESEARCH DESIGN AND METHODS: The LEADER trial (NCT01179048) was a randomized, double-blind, multicenter, CV outcomes trial assessing liraglutide (1.8 mg/day) versus placebo, in addition to standard of care, for up to 5 years. Information on DFUs was collected systematically during the trial, and DFU complications were assessed post hoc through reviewing case narratives. RESULTS: During a median of 3.8 years’ follow-up, similar proportions of patients reported at least one episode of DFU in the liraglutide and placebo groups (3.8% [176/4,668] versus 4.1% [191/4,672], respectively; hazard ratio [HR] 0.92 [95% CI 0.75, 1.13; P = 0.41]). Analysis of DFU-related complications demonstrated a significant reduction in amputations with liraglutide versus placebo (HR 0.65 [95% CI 0.45, 0.95; P = 0.03]). However, no differences were found for foot infections, involvement of underlying structures, or peripheral revascularization in the main analysis. CONCLUSIONS: Treatment with liraglutide in patients with type 2 diabetes and at high risk of CV events in the LEADER trial did not increase the risk of DFU events and was associated with a significantly lower risk of DFU-related amputations compared with placebo. This association, possibly due to chance, needs further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Diamicron MR Controlled Evaluation (ADVANCE) studies, but DFU was not a specified end point in these trials (11,20,21).”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“In the Veterans Affairs Diabetes Trial (VADT), amputation due to ischemic gangrene was included within the composite primary end point, but data related to amputation or foot ulcers only do not appear to have been published (22,23).”
BackgroundDiabetic foot ulcers and their recurrence
Armstrong, D. G., Boulton, A. J. M., & Bus, S. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1615439 · Cited by 4,376 · cited 7×
“In the longer term, however, there is a high risk that DFUs will recur (1).”
BackgroundInfluentialGupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Cited by
Items 101–140 of 140
Rosenzveig, A., Tefera, L. T., Agrawal, A., Rajendran, J., Massad, F., Badwan, O. Z., Wajsberg, J. R., Chaudhury, P., Zidar, D. A., Paul, T. K., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.045664 · Cited by 2
Tulamo, R. M., Bradbury, A., Hicks, C. W., Gottsäter, A., Gupta, P. C., Rother, U., Sigvant, B., & Hinchliffe, R. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00845-7 · Cited by 2
Zima, J., & Jairath, N. N. (2023) · Journal of Wound Ostomy and Continence Nursing · doi:10.1097/won.0000000000001009 · Cited by 2
Multidisciplinary Management of Chronic Limb Threatening Ischemia
Naveh, S., Rogers, R. K., Hess, C. N., Nehler, M. R., Hsia, J. A., & Bonaca, M. P. (2024) · JACC Case Reports · doi:10.1016/j.jaccas.2024.102717 · Cited by 2
Series: Cardiovascular outcome trials for diabetes drugs Liraglutide and LEADER
Fisher, M. (2020) · British Journal of Diabetes · doi:10.15277/bjd.2020.267 · Cited by 2
Canale, M. P., Federici, M., & Cola, G. D. (2021) · Italian Journal of Vascular and Endovascular Surgery · doi:10.23736/s1824-4777.21.01492-3 · Cited by 2
Sodium-Glucose Cotransporter 2 Inhibitors and Amputations
Clements, J. N. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.8134 · Cited by 1
Imanbayev, M., Kozhakhmetov, Z., Salmenbayev, Y., Toleutayeva, D., & Kazymov, Y. (2025) · Journal of Surgical Research · doi:10.1016/j.jss.2025.02.006 · Cited by 1
Gouda, P., Secemsky, E. A., Hess, C. N., Arya, S., Fokorede, F., Mehran, R., Bonaca, M. P., Patel, M. R., & Jones, W. S. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107446 · Cited by 1
Association between glycaemic control and diabetic foot outcomes: Dark side of the moon?
Vas, P. R. J., Whyte, M., & Παπάνας, Ν. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107650 · Cited by 1
Detection, management, and prevention of diabetes-related foot disease in the Australian context
McNeil, S. E., Waller, K., Lorenzo, Y. S. P., Mateevici, O. C., Telianidis, S., Qi, S. D., Churilov, I., MacIsaac, R. J., & Galligan, A. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i7.942 · Cited by 1
Billeter, A. T., & Müller-Stich, B. P. (2019) · Der Chirurg · doi:10.1007/s00104-018-0786-z · Cited by 2
Evaluation of US2019070266 patent, treatment diabetic foot ulcers with Liraglutide
Pérez-Santos, M. (2020) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.5093195
Inhibiteurs des SGLT2 et risque d’amputations des membres inférieurs : plus de peur que de mal ?
Scheen, A. J. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.01.015 · Cited by 1
Kaur, K. K. (2020) · Open Access Journal of Endocrinology · doi:10.23880/oaje-16000145
Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: Beyond Glycemic Control
La Salle, J., Uusinarkaus, K., Family Medicine, C. P. C., Marso, S. P., Cardiovascular Medicine, H. M. H., & Pantalone, K. M. (2023) · Journal of Family Medicine · doi:10.26420/jfammed.2023.1325
Peripheral arterial disease and the cardiometabolic syndrome: assessment and management
Heiß, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00015-2
Relative and Absolute Risks of Adverse Events with Real-World Use of SGLT2 Inhibitors in CKD
Odutayo, A., & Levin, A. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000148
Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
Hong, S. (2023) · BIO Web of Conferences · doi:10.1051/bioconf/20236101006
Managing Diabetes in Patients with Foot Complications
Subramanian, V., & Jude, E. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-05832-5_4
Type 2 diabetes beyond glycaemic control: the impact of disease severity and therapy
Werkman, N. C. C. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231221nw
Walker, M., & Beckman, J. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13593-4.00008-1
Risk Factors for Claudication and Management to Modify Them
Devadoss, R., & Alonso, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-02460-2_7
Werkman, N. C. C., Driessen, J. H. M., Stehouwer, C. D. A., Vestergaard, P., Schaper, N. C., van den Bergh, J. P., & Nielen, J. T. H. (2024) · Figshare · doi:10.6084/m9.figshare.26600980
Critical Limb Ischaemia: Overview and Medical Treatment
Brandolin, B., & Visonà, A. (2026) · Springer eBooks · doi:10.1007/978-3-031-82232-2_30
Caradu, C. (2020) · theses.fr (ABES) · doi:10.70675/7e30d752z9f28z4e3cz859ezdf2097118a58 · Cited by 1
Zhang, C., Wan, Q., Zhou, H., & Li, Y. (2026) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2026.2658715
Associations between GLP 1 receptor agonist therapy and surgical wound healing in a high-risk cohortPreprint
Pullmann, D., Adams, J. C., Belostotsky, H., Mestvirishvili, T., Chiu, M. E., Oh, C., & Rabbani, P. S. (2026) · medRxiv · doi:10.64898/2026.04.21.26351321
James, F., Li, Q., Somisetty, M., Nguyen, C., Vaughan‐Sarrazin, M., Lund, B. C., Tsai, S. X., Smolderen, K. G. E., Hoffman, R. M., Arya, S., et al. (2026) · medRxiv · doi:10.64898/2026.06.18.26356017
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.032
Amani‐Beni, R., Darouei, B., Maleki, S., Sadri, H., Seifnezhad, A., Eshraghi, R., Bahrami, A., Ebrahimi, P., Shahid, F., Upadhyaya, S., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02271-4
Goldenberg, R. (2026) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2026.4149
Long, X., Qiu, Y., Lin, Z., Liu, Y., Fang, J., Wang, Y., Li, Y., Sun, Y., Zeng, S., & Huang, K. (2026) · Dermatologic Therapy · doi:10.1155/dth/9612721
Zhang, T., Luo, X., Chen, C., Zhang, Y., Xu, B., He, Z., & Zhou, J. (2026) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346261487722
Semaglutide and limb events: expanding the cardiovascular prevention paradigm?
Canonico, M. E., & Bonaca, M. P. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag494
Khadija, H. A., Alnees, M., Abdullah, A., Ibraheem, K., Makhlouf, T. Z., Cohen, R., Najajra, D., Twito, O., Schiller, T., & Kirzhner, A. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101794
Pan, J., Guo, C., Huang, Q., Zhang, Y., Shen, Y., & Guo, C. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm55884
Diabetic Foot: An Unmet Opportunity for the Novel Antidiabetic Agents?
Koufakis, T., Popovic, D. S., Patoulias, D., & Παπάνας, Ν. (2026) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346261501339
Beraja, G. E., & Levine, J. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.10.010
Metadata
- Authors
- Dhatariya, K., Bain, S. C., Buse, J. B., Simpson, R., Tarnow, L., Kaltoft, M. S., Stellfeld, M., Tornøe, K., Pratley, R. E., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators
- Affiliations
- Norfolk and Norwich University Hospital (GB)
- University of East Anglia (GB)
- Corresponding author
- Dhatariya, Ketan
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-08-02
- Volume
- 41
- Issue
- 10
- Pages
- 2229-2235
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6150424
- OpenAlex
- W2883426762
- Semantic Scholar
- 27723cc2089089c747770bb1f4a89c5cf9dd9df2
- Cited by
- 141
- References
- 30
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 19 · 2023: 20 · 2022: 21 · 2021: 16 · 2020: 10 · 2019: 10 · 2018: 2
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- liraglutide, diabetic foot ulcer, type 2 diabetes, amputation, foot infection, peripheral revascularization, cardiovascular risk, GLP-1 receptor agonists, LEADER trial, post hoc analysis
- MeSH terms
- Liraglutide, Aged, Amputation, Surgical, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Diabetic Foot
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.